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Abstract
The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive
therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL)
prior to initiating osteotoxic therapy, little is known about the alterations to the bone marrow microenvironment during
leukemogenesis. Therefore, in this study, we focused on the development of precursor-B cell ALL (pre-B ALL) in an
immunocompetent BCR-ABL1+ model. Here we show that hematopoiesis was perturbed, B lymphopoiesis was impaired,
collagen production was reduced, and the number of osteoblastic cells was decreased in the bone marrow microenvironment.
As previously found in children with ALL, the leukemia-bearing mice exhibited severe bone loss during leukemogenesis.
Leukemia cells produced high levels of receptor activator of nuclear factor κB ligand (RANKL), sufficient to cause
osteoclast-mediated bone resorption. In vivo administration of zoledronic acid rescued leukemia-induced bone loss, reduced
disease burden and prolonged survival in leukemia-bearing mice. Taken together, we provide evidence that targeting
leukemia-induced bone loss is a therapeutic strategy for pre-B ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common
cancer among children and remains a frequent cause of
death from cancer before 20 years of age [1, 2]. Survival for
children and adolescents with ALL has greatly improved
over recent decades, with long-term survival now exceeding
85%, primarily due to combination therapies, improved
supportive care, and the introduction of novel agents such
as tyrosine-kinase inhibitors [1–6]. A significant gain in
clinical outcome has been achieved through better predic-
tion of survival, based on refined risk stratification of
patients. The detection of minimal residual disease is the
single most powerful predictor, and is critical in selecting
optimal therapy for each patient [1, 4, 6]. However, out-
comes in high-risk subgroups and salvage rates remain
poor, including those with BCR-ABL1 fusion, BCR-ABL1-
like ALL, T-cell ALL (T-ALL), and infant ALL [1, 5, 7–9].
Further intensification of current multi-agent chemotherapy
is associated with increased toxicity, and hematopoietic
stem cell transplantation is an option for patients who are
considered to be at very high risk of treatment failure.
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Hence, finding less toxic and more effective therapies for
high-risk ALL subgroups is vital.
Advances in immunological approaches have led to the
development of novel therapies for immune checkpoint
blockade and the targeting of surface antigens on leukemic
cells. Genetically modified antibodies directed at CD19,
CD20, CD22 and CD30 antigens on hematopoietic tumors
have been reported to demonstrate anti-leukemic activity as
single agents [10–13]. Initial chimeric antigen receptor T-
cell therapies were developed to primarily target the CD19
cell surface antigen that is present at high density on most
precursor-B cell ALL (pre-B ALL). In pioneering clinical
trials, potent effects have been demonstrated in relapsed and
refractory pre-B ALL [11, 14, 15]. Immunological approa-
ches have the capacity to overcome chemotherapy
resistance.
Another novel therapeutic approach is targeting the
microenvironment of hematopoietic tumors [16, 17]. The
role of the bone marrow microenvironment (BMM) in
driving disease progression is widely recognized, with
chemokine receptors (CXCR4), adhesion molecules, signal
transduction pathways and hypoxia-related proteins playing
a role [18–26]. The recent recognition that the tumor
microenvironment contributes to treatment failure or suc-
cess has highlighted the need to improve our understanding
of the signaling programs elaborated by the microenviron-
ment [27, 28]. Could existing cancer therapies be improved
by the addition of novel therapies directed at signaling
programs? It is well documented that malignant cells have
the capacity to remodel the BMM, thereby promoting dis-
ease development [22, 23, 25, 26, 29–34]. To identify novel
targets and signaling programs, greater understanding of the
complex interactions within the BMM is required.
Exploiting unique properties of the leukemia micro-
environment has great potential.
Pre-B ALL is the most common form of leukemia in
children. Symptoms at the time of presentation include
bruising, bleeding, pallor, fatigue, and infections [1].
More than 35% of patients suffer from musculoskeletal
pain, and skeletal abnormalities are frequently present at
diagnosis [35]. Low serum markers of bone formation
have been recorded prior to commencing therapy, and
bone histomorphometric assessment has identified a
reduction in trabecular bone volume as well as trabecular
thickness [35–37]. Bone marrow trephines at diagnosis
of pediatric ALL show lower percentages of adipocytes,
osteoblasts and osteoclasts, strongly suggesting that
ALL cells have the capacity to alter the BMM [38].
However, their precise impact on hematopoiesis, bones
and BMM remain obscure. To elucidate the impact of
leukemia development in pre-B ALL, we generated and




MSCV vector coexpressing human BCR-ABL1 (p185) and
mCherry (MSCV-BCR-ABL1-IRES-mCherry) was
obtained from St Jude Children’s Research Hospital,
Memphis, TN, USA and has been previously described
[39]. 293T cells were transfected with pMD-old-gag-pol,
pCAG-Eco and MSCV-BCR-ABL1-IRES-mCherry using
FuGENE 6 (Promega, Madison, WI, USA). At 48 h after
transfection, viral supernatants were collected, filtered, and
stored at −80 °C.
Mouse Modeling of BCR-ABL1 pre-B Leukemia
Seven to 10-week old C57BL/6J mice were purchased from
the Animal Research Centre, Perth. Animals were housed
under pathogen-free conditions and all studies were
approved by the Animal Ethics Committee, Telethon Kids
Institute, Perth. Bone marrow cells from C57BL/6 J mice
were extracted from femurs and tibias and transduced with
MSCV-BCR-ABL1-IRES-mCherry retroviral supernatant
supplemented with 100 ng/mL stem cell factor, 10 ng/mL
IL-6, 50 ng/mL thrombopoietin, and 5 ng/mL Flt3 ligand
(R&D Systems, Minneapolis, MN, USA) at 2500 rpm for 2
h at room temperature. One million unsorted cells were
transplanted into lethally irradiated (two doses of 550 cGy
with a 2 h interval between doses) recipients (Recipient 1)
via tail vein injections (Fig. 1a). Irradiation of recipient
mice was not required in the secondary transplantation of
leukemia cells (Recipient 2). Leukemia cells harvested from
Recipient 2 were expanded and maintained in RPMI sup-
plemented with 10% fetal calf serum,
penicillin–streptomycin (Thermo Fisher Scientific, Wal-
tham, MA, USA), glutamine and 55 μM 2-mercaptoethanol.
All experiments were conducted using tertiary transplanta-
tion recipients (Recipient 3). Each recipient received 1000
leukemia cells, except for the homing study where 106 cells
were transplanted.
Flow Cytometry and Cell Sorting (FACS)
All FACS studies were performed using single cell sus-
pensions, and cells were stained using standard protocols.
Flow cytometry was performed on a BD Fortessa and FACS
on a FACSAria. Cell suspensions were counted using a Vi-
CELL® Cell Viability Analyzer (Beckman Coulter, India-
napolis, Indiana, USA). BD HorizonTM Fixable Viability
Stain 700 (BD Biosciences, Franklin Lakes, NJ, USA) was
used for exclusion of dead cells. For phenotypic analysis of
mouse bone marrow hematopoietic cells, mononucleated
cells were treated with Red Blood Cell Lysis Buffer
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(Thermo Fisher Scientific) and stained with CD45−FITC,
B220-PerCP-Cy5.5, CD19−APC-H7, CD43-BV421, IgM-
PE-Cy7, IgD-BV786, CD11b-BV605, Ly6G-APC-H7,
Ly6C-BV421, F4/80-PE, CD3-BV510, and NK1.1-BV786.
For phenotypic analysis of leukemia cells, CD19-APC-H7,
CD24-APC, and BP-1-PE were used. For phenotypic ana-
lysis of bone marrow stromal cells, femurs and tibias were
crushed and incubated with 337.5 U/mL collagenase
 BCR-ABL1 + mCherry
Recipient 1
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(Worthington Biochemical Corp., Lakewood, NJ, USA) and
40 U/mL DNase I (Sigma-Aldrich, NSW, Australia) at 37 °
C for 60 min in a shaking water bath. Digested bone frag-
ments were filtered through sterile 100 μm strainers.
Mononucleated cells were treated with Red Blood Cell
Lysis Buffer and stained with CD45-PerCP-Cy5.5 and
Ter119-PerCP-Cy5.5 for exclusion of hematopoietic cells.
Subtypes of bone marrow stromal cell were identified using
Sca-1-BV510, CD31-FITC, PDGRFα-APC, PDGFRβ-PE,
and CD51-biotin/streptavidin-BV421. To enumerate bone
marrow fibroblasts, cells were fixed, permeabilized, and
stained with vimentin-APC (R&D Systems). For purifica-
tion of bone marrow stromal cells, CD45-PerCP-Cy5.5 and
Ter119-PerCP-Cy5.5 were used to exclude the hemato-
poietic cells. For purification of pre-B cells, CD19-APC-
H7, CD24-APC, BP-1-PE, and IgM-PE-Cy7 were used.
Tissue Processing and Immunohistochemistry
For histological analysis, femurs were fixed in 4% paraf-
ormaldehyde (Sigma Aldrich) in PBS at 4 °C for 48 h and
decalcified in 10% EDTA at 4 °C for 8 days. Tissues were
embedded in paraffin and were cut at 5 μm thick for
immunohistochemistry, hematoxylin and eosin staining, or
tartrate-resistant acid phosphatase (TRAP) staining. The
slides were first incubated at 60 °C for 45 min and then
deparaffinized using a Leica Autostainer XL (Leica micro-
systems, Wetzlar, Germany). For TRAP staining, slides
were immersed in pre-warmed TRAP staining solution (50
mM sodium acetate (pH 5.2), 0.15% Naphthol-AS-TR-
phosphate, 50 mM sodium tartrate, and 0.1% Fast Red TR)
at 37 °C in the dark for 30 min and were counterstained with
hematoxylin (Vector Labs, Burlingame, CA, USA). Images
were obtained using Pannoramic MIDI (3DHistech Ltd,
Budapest, Hungary). Bone histomorphometry parameters
were then analyzed using BIOQUANT OSTEO software
(BIOQUANT Image Analysis Corporation, Nashville, TN,
USA). For collagen staining, deparaffinized femoral sec-
tions were stained with collagen type I antibody (Abcam,
Cambridge, MA, USA) overnight at 4 °C followed by
biotinylated goat anti-rabbit IgG (VectorLabs, Burlingame,
CA, USA). The slides were included with
avidin–biotin–peroxidase complex (VectorLabs) and were
counterstained with hematoxylin. Images were obtained
using a Nikon Ti-E microscope and were analyzed by NIS
software modules (Nikon Instruments Inc., Melville, NY,
USA).
Microcomputed Tomography (Micro-CT) Analysis
Fixed femoral bone samples were immobilized in a 2-mL
tube filled with PBS for micro-CT scanning. Samples were
loaded into the bed of a Skyscan 1176 micro-CT scanner
(Bruker, Kontich, Belgium) and the distal femur from
midshaft to the distal articular surface was scanned using
the following parameters: 50 kV, 500 µA, 1000 ms, 0.5 mm
Al filter, 9-µm pixel resolution, rotation step of 0.4°, frame
averaging of 2. Scans were reconstructed using NRecon
software (Bruker) at a constant threshold value, and then
orientated for analysis using DataViewer software (Bruker).
Trabecular bone parameters were analyzed within the sec-
ondary spongiosa, defined as a region beginning 0.5 mm
below the bottom of the growth plate and extending 1 mm
proximally, and excluding the cortical bone. Cortical bone
parameters were analyzed within the mid-diaphyseal region
located 4.5 mm proximal to the base of the distal growth
plate and extending for 1 mm in height proximally.
Enzyme-linked immunosorbent assay (ELISA)
Analyses
Blood was collected via cardiac puncture and kept undis-
turbed at room temperature for 2 h. Sera were removed by
centrifuging at 5500 rpm for 10 min and stored at −80 °C.
Carboxy−terminal cross-linked telopeptides of type 1
collagen (CTX) ELISA was performed in duplicate
according to manufacturer’s instructions (AC-06F1,
Immunodiagnostic Systems, Tyne & Wear, United King-
dom). To measure receptor activator of nuclear factor κB
ligand (RANKL) protein levels from the cell supernatants
after 48 h culture and bone marrow supernatants after
flushing the bone marrow with 500 μL of PBS, RANKL
Quantikine ELISA kit (R&D Systems) was used and the
assay was performed in duplicate according to manu-
facturer’s instructions.
Fig. 1 Pre-B leukemia impairs hematopoiesis in the bone marrow. a
Schematic representation of the experimental model. The normal bone
marrow cells were transduced with MSCV-BCR-ABL1-IRES-
mCherry retrovirus and transplanted into lethally irradiated Recipient
1. All subsequent transplantations were performed using non-irradiated
recipients. b Kaplan–Meier survival curve of mice transplanted with
1000 BCR-ABL1 ALL cells (n= 24 mice). c Percentage of mCherry+
cells in bone marrow, spleen and blood during leukemia development.
d Number of hematopoietic cells (CD45+mCherry−) in the bone
marrow during leukemia development. e Percentage of B220+ cells in
the CD45+mCherry− fraction during leukemia development. f Per-
centage of CD11b+ cells in the CD45+mCherry- fraction during leu-
kemia development. g Percentage of NK1.1+ cells in the CD45
+mCherry- fraction during leukemia development. h Composition of B
cell subpopulations during leukemia development (percentage in the
B220+CD45+mCherry- fraction). c-h Bone marrow cells were har-
vested from one femur and two tibias (Day 8, 10, 13, 15, and 16: n= 4
mice; Day 17: n= 3 mice; Day 20: n= 6 mice). i Representative
images of immunostaining for collagen I (brown) from WT and mice
at Day 8 and Day 20 post leukemia cell injection (scale bars, 50 μm)
(left) and quantification of the percentage of collagen I per surface area
(n= 3) (right). Throughout, *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001. Error bars represented mean ± SD
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Western Blotting
Cells were harvested, sectioned and lysed in Evan’s protein
lysis buffer (1 mM EDTA, 1 mM EGTA, 1%NP-40, 50 mM
Tris-HCl, 120 nM NaCl and peptide inhibitors). Ten
micrograms of protein extracts from each cell line were
separated electrophoretically (SDS-PAGE). The membrane
was blocked with 5% milk in PBS and stained with rabbit
anti-mouse sRANKL antibody (Abcam) and anti-rabbit
horseradish peroxidase (GE Healthcare, Pittsburg, PA,
USA). Horseradish peroxidase activity was detected with a
chemiluminescence detection kit. After exposure and
development of the film, the membrane was stripped and re-
probed for housekeeping protein mouse anti-β-Actin
(Sigma-Aldrich). Images were obtained using ImageLab
Software (Bio-Rad, Hercules, CA, USA).
RNA Extraction and Quantitative Reverse
Transcription PCR
Total RNA was extracted from mCherry+ leukemia cells,
bone marrow stromal cells (CD45-Ter119-), B cells (B220+),
and pre-B cells (CD19+CD24+BP-1+IgM-) using RNeasy
Mini Kit or RNeasy Micro Kit with RNase-free DNase I
(Qiagen, Hilden, Germany). cDNA was synthesized using
SuperScript VILO Master Mix (Thermo Fisher Scientific).
Quantitative PCR was performed on an ABI 7900HT ther-
mocycler using Taqman Gene Expression Assays (Thermo
Fisher Scientific) for mouse Rankl (Mm00441906_m1),
Csf1 (Mm00432686_m1), Opg (Mm00435454_m1), Pax5
(Mm00435501_m1) as well as Hprt (Mm03024075_m1),
and SYBER Green (Qiagen) with the following specific
primer set: osteocalcin F: GCGCTCTGTCTCTCTGACCT,
osteocalcin R: ACCTTATTGCCCTCCTGCTT, Hprt
F: GCAGTACAGCCCCAAAATGG, Hprt R: AACAAA
GTCTGGCCTGTATCCAA. Relative expression was cal-
culated using the ΔΔCT method normalized to Hprt levels
for each individual sample measured in duplicate.
Co-culture Study
A total of 1 × 104 RAW 264.7 cells were seeded in 24-well
plates in triplicate and cultured for 8 days in the presence of
20 ng/mL of RANKL protein (Abcam) or 1 × 105 leukemia
cells with a change of medium every 2 days. The cells were
fixed and TRAP staining was performed.
In vitro Zoledronic Acid Study
A total of 1 × 104 leukemia cells were seeded in 96-well
plates in triplicate and cultured for 48 h in the presence of 1
μM or 10 μM of zoledronic acid. Ten microliters of ala-
marBlue were added and colorimetric changes were
measured by Synergy Mx Microplate Reader (BioTek,
Winooski, VT, USA) at wavelengths of 570 nm and 600
nm. Percentage of alamarBlue reduction was calculated
using standard formula. For the colony forming assay, 1 ×
103 leukemia cells were seeded in 6-well plates in triplicate
and cultured for 7 days in the presence of 10 μM of zole-
dronic acid in Mouse Methylcellulose Complete Media for
Pre-B Cells (R&D Systems).
In vivo Zoledronic Acid Treatment
Mice were given a daily intraperitoneal (ip) injection of 2 μg
of zoledronic acid (Selleckchem, Houston, TX, USA) in
100 μL PBS or 100 μL of PBS alone, 5 days a week for
2 weeks. Treatment was started at 3 days post leukemia cell
injection.
Statistical Analyses
Statistical analyses and graphics were performed using
Prism 7 (GraphPad, La Jolla, CA, USA) and Microsoft
Excel for Mac 2011. Data were analyzed using the two-
tailed unpaired Student’s t-test. Survival studies were
analyzed using log-rank test. The results are presented as
means ± standard deviation (SD). A P value < 0.05 was
considered as statistically significant. No statistical test
was used to determine the sample size. No randomization
was used in animal studies. The survival studies were
blinded.
Results
An immunocompetent murine model of pre-B ALL
We developed and characterized an immunocompetent
BCR-ABL1+ model (Fig. 1a). Normal bone marrow cells
were transduced with MSCV-BCR-ABL1-IRES-mCherry
retrovirus and transplanted into lethally irradiated reci-
pients, and they developed pre-B ALL. Secondary reci-
pients received leukemia cells without any pre-
conditioning. The BCR-ABL1+ cells isolated from the
secondary recipients were confirmed to express B-lineage
markers and they could be expanded and maintained in
culture (Supplementary Figure 1A) [39]. Experiments were
performed using immunocompetent recipients injected with
1000 BCR-ABL1+ cells, thus avoiding irradiation-induced
changes to the microenvironment. Leukemia cells homed to
bone marrow and spleen, and mice developed BCR-ABL1+
leukemia within 3 weeks (Fig. 1b; Supplementary Fig-
ure 1B). Leukemia cells remained at a low level of <1% for
10 days, followed by rapid expansion in bone marrow and
spleen, and slightly later in blood (Fig. 1c).
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Pre-B leukemia impairs hematopoiesis in the bone
marrow
In order to detect any changes in the hematopoietic and
stromal bone marrow compartments due to the presence of
low levels of leukemia cells, we used a range of techniques,
methodically assessing hematopoiesis, extracellular matrix
(ECM) and bone marrow stroma (Supplementary Figure 2).
Leukemia mice showed a reduction of normal hemato-
poietic cells (CD45+mCherry−) in the bone marrow
(Fig. 1d) and massive splenomegaly (Supplementary Fig-
ure 1C). Further, we observed lower proportions of B cells,
and higher proportions of myeloid and NK cells but not
CD3+ T cells (Fig. 1e–g; Supplementary Figure 1D),
accompanied by increased proportions of neutrophils,
Ly6clo monocytes and macrophages (Supplementary Fig-
ure 1E). Starting on Day 15, we recorded a significant
increase of pro-B cells and a corresponding drop in pre-B
cells within the B220+ fraction, suggesting leukemia
development impairs the pro-B to pre-B differentiation
(Fig. 1h).
Leukemia reduces collagen type I and decreases the
number of endothelial and osteoblastic cells in the
bone marrow
To test the effect on the ECM and bone marrow stromal
compartment, we examined the level of collagen type I by
immunohistochemistry, and enumerated the subpopulations
of stromal cells by flow cytometry using enzymatically
digested bones. The content of collagen type I was sig-
nificantly reduced in femurs at Day 8 and Day 20 post
leukemia cell injection (Fig. 1i). While leukemia did not
affect the number of mesenchymal stem/stromal cells
(MSCs) [40], PDGFRα+Sca-1+ (PαS) mesenchymal cells
[41], CXCL-12 abundant reticular cells [42] and vimentin+
fibroblasts [43], we observed significantly lower numbers of
endothelial and osteoblastic cells (Fig. 2a, b; Supplementary
Figure 3). Consistent with this, expression of osteocalcin
mRNA was significantly reduced in bone marrow stromal
cells from leukemia mice, as compared to wild type (WT)
mice (Fig. 2c). Collectively, our results demonstrated that
the presence of pre-B ALL cells perturbs hematopoiesis and
alters the BMM.
Leukemia induces bone loss
Next we investigated the effect of leukemia cells on
bones. Strikingly, we found progressive bone loss over
the course of the disease (Fig. 2d). Although leukemia did
not affect the cortical bone in the mid-femoral diaphyseal
region (Supplementary Figure 4), leukemia mice exhib-
ited loss of trabecular structures in the metaphyseal region
of distal femurs (Fig. 2e). At Day 13 and 20, trabecular
spacing was significantly increased and trabecular num-
bers were decreased in leukemia mice (Fig. 2f, g). Micro-
CT analysis also revealed severe loss of cortical bone in
the same region from Day 10 onward (Fig. 2h, i). Thus,
development of pre-B leukemia induces bone loss, and
this model recapitulates the clinical symptoms of
decreased bone mass in children diagnosed with ALL
[35].
Leukemia enhances the activity of osteoclasts
Bone homeostasis relies on balanced activities of osteo-
blastic cells and osteoclasts. To determine whether the
observed bone loss could be the result of increased osteo-
clast activity, we evaluated the osteoclast-mediated bone
resorption during leukemia development. Histologic bone
sections revealed high TRAP activity at Day 10 and 13,
indicating the TRAP+ osteoclasts were highly active
(Fig. 3a). The number of TRAP+ multinucleated osteoclasts
was elevated at Day 10 (Fig. 3b), and the number of TRAP+
multinucleated cells per bone surface increased significantly
from Day 10 onwards (Supplementary Figure 5A). On Day
20 the TRAP+ multinucleated osteoclasts were significantly
reduced, which correlates with the loss of trabecular struc-
ture, as shown in Fig. 2d. Consistent with osteoblastic cells
detected by flow analysis (Fig. 2b), the number of osteo-
blastic cells was reduced at the late stage of disease
development (Supplementary Figures 5B and C). To eval-
uate the bone resorption activity during leukemia develop-
ment, we measured serum levels of CTX, a marker of bone
resportion, by ELISA. On Day 10 the CTX level was sig-
nificantly higher compared to control (Fig. 3c), supporting
the findings from TRAP measurements. At Day 16 CTX
levels were significantly lower, which could be explained
by reduced numbers of osteoclasts later in leukemia
development (Fig. 3b).
Fig. 2 Pre-B leukemia induces bone loss in vivo. a, b Bone marrow
cells were harvested from one femur and two tibias after enzymatic
dissociation (Day 8, 10, 13, 15, and 16: n= 4 mice; Day 17: n= 3
mice; Day 20: n= 6 mice). a Number of endothelial cells. b Number
of osteoblastic cells. c Mean expression of osteocalcin (Bglap) in bone
marrow CD45− cells (WT), CD45+ (WT) and in CD45− cells in
leukemia-bearing mice at Day 16 post leukemia cell injection (n= 3).
d 3D rendering of distal femur bone compartment (top panels: long-
itudinal sections; bottom panels: axial sections). Representative cor-
tical and trabecular bones in the distal femurs of mice at stated days
post leukemia cell injection (false colored images, n= 4 mice per time
point). e–g Micro-CT analysis of femoral trabecular bone (n= 4 mice
per time point). e Bone volume/total volume (BV/TV). f Trabecular
spacing (Tb.Sp). g Trabecular number (Tb.N). h–i Micro-CT analysis
of femoral cortical bone at trabecular zone (n= 4 mice per time point).
h Cortical volume. i Cortical thickness. Throughout, *P < 0.05, ** P <
0.01, *** P < 0.001, **** P < 0.0001. Error bars represented mean ±
SD
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Fig. 3 Pre-B ALL increases the activity of osteoclasts and produces
high levels of RANKL. a Representative images of paraffin sections of
distal femur bone compartment stained for the osteoclastic marker
TRAP at stated days post leukemia cell injection (n= 4 mice per time
point, scale bars, 50 μm). b Quantification of TRAP+ osteoclasts in the
distal femur bone compartment. c Serum levels of CTX in WT and
leukemia mice (WT, Day 4, 8, and 10: n= 4 mice; Day 16: n= 3
mice). d Mean expression of Rankl and Csf1 in B220+ cells in WT
mice relative to that in mCherry+ cells in mice at Day 10 and 16 post
leukemia cell injection (WT, Day 10: n= 4 mice; Day 16: n= 3 mice).
e Leukemia cells were cultured for 48 h and the level of RANKL in the
supernatants was measured by ELISA (n= 3). f Representative wes-
tern blot of RANKL from leukemia cell lysate (n= 3). Lane 1 is B220
+ cell lysate and Lane 2 is leukemia cell lysate. β-actin was used as a
loading control. g RANKL levels measured by ELISA in bone marrow
supernatants from control and leukemia mice (n= 3). h Representative
images of RAW 264.7 cells stained for TRAP after culture with 20 ng/
mL RANKL or 1 × 105 leukemia cells for 8 days (scale bars, 100 μm)
(left) and quantification of the TRAP+ multinucleated osteoclasts (n=
3) (right). iMean expression of Pax5 in pre-B cells (CD19+CD24+BP-
1+IgM−) in WT mice relative to that in BCR-ABL1+ cells (Fig. 1a)
and in mCherry+ cells in mice at Day 16 post leukemia cell injection
(n= 3). Throughout, *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001. Error bars represented mean ± SD
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Leukemia cells produce RANKL and osteoclast-
mediated bone resorption
Osteoclasts differentiate from myeloid precursors under
the influence of RANKL, macrophage colony stimulating
factor (M-CSF), and a soluble receptor antagonist
RANKL, termed osteoprotegerin (OPG) [44]. To gain
insight into the mechanism of osteoclast-mediated bone
resorption, we evaluated mRNA expression of Rankl
(Tnfsf11), M-CSF (Csf1), and Opg in leukemia cells. Opg
mRNA was undetectable in the leukemia cells and con-
trols, and Csf1 mRNA expression in leukemia cells was
similar to controls (Fig. 3d). In contrast, expression of
Rankl mRNA in leukemia cells was 50–100-fold higher
than controls (Fig. 3d). In addition, abundant RANKL
protein was detected in cell lysates and culture super-
natants (Fig. 3e, f). ELISA analysis confirmed that Day 15
leukemia mice contained 20-fold higher levels of RANKL
protein in the bone marrow supernatant than control mice
(Fig. 3g). We further elucidated the effect of RANKL
produced by leukemia cells on the osteoclasts by co-
culturing the leukemia cells with the RAW 264.7 murine
cell line [45]. We clearly observed that RAW 264.7 cells
differentiated into TRAP+ osteoclasts in the presence of
leukemia cells (Fig. 3h), confirming that RANKL secreted
by leukemia cells is responsible for the osteoclast-
mediated bone resorption. In addition, RANKL is docu-
mented to be strongly repressed by PAX5, which is a cri-
tical B-lymphoid transcription factor, and genetic lesions
in PAX5 are widespread in pre-B ALL, generally leading
to reduced expression [46–48]. We found Pax5 mRNA
levels in Day 16 leukemia cells to be significantly lower
compared to WT pre-B cells (Fig. 3i). Collectively, these
findings highlight an important role for osteoclast-
mediated bone loss in leukemia.
Zoledronic acid reduces leukemia burden and
improves survival in mice
We next determined whether targeting the BMM could
reduce the development of pre-B ALL. Given that osteo-
clasts are key effectors of leukemia-induced bone loss in our
model, we assessed the efficacy of zoledronic acid, an
osteoclast inhibitor, with treatment starting on Day 3 post
leukemia cell injection (Fig. 4a). Zoledronic acid inhibited
the activity of osteoclasts, restored the bone loss and
reduced the bone resorption activity without direct effect on
homing, colony forming capacity and viability of the leu-
kemia cells (Fig. 4b–f; Supplementary Figure 6 and 7A).
Notably, mice treated with zoledronic acid showed sig-
nificantly lower leukemia burden in bone marrow, spleen
and blood, as well as higher numbers of normal bone
marrow cells compared to control mice at Day 15 (Fig. 4g,
h). Administration of zoledronic acid prolonged survival
in our aggressive leukemia model (Fig. 4i). As expected, at
the time the mice succumbed to leukemia the disease bur-
den was similar in all groups (Supplementary Figure 7B and
C). These findings raise the possibility that osteoclasts may
serve as therapeutic targets in pre-B ALL that is frequently
associated with bone loss.
Discussion
The main strategy for cancer therapy has focused on tar-
geting malignant cells, leading to markedly improved cure
rates for pediatric cancers. However, the recent recognition
that the tumor microenvironment contributes to treatment
failure or success has led to a paradigm shift [27, 28]. The
BMM is essential for normal hematopoiesis, but also for
leukemogenesis [26, 49, 50]. Bone marrow is a complex
organ, containing many different hematopoietic and non-
hematopoietic cell types that are surrounded by a shell of
vascularized and innervated bone. Interactions among these
cell types, secreted factors and the ECM form an intricate
network that is clearly abnormal in hematopoietic
malignancies.
The salient features of our pre-B ALL model are the
injection of only 1000 BCR-ABL1+ cells into immuno-
competent recipients, and without incurring any irradiation-
induced damage. We observed that leukemia development
perturbs hematopoiesis and impairs B-lymphopoiesis. This
could be explained by leukemogenesis resulting in the altered
function of the hematopoietic stem and progenitor cells [51].
Importantly, we documented severe bone loss clearly shown
by Micro-CT imaging (Fig. 2d), recapitulating the clinical
Fig. 4 Zoledronic acid reduces leukemia burden and improves survival
in mice. a Schematic diagram of zoledronic acid treatment schedule. b
Leukemia cells were incubated with 0, 1 μM, or 10 μM of zoledronic
acid for 48 h. Cell viability was evaluated by alamarBlue assay (n= 4).
c Representative images of colony forming cells from leukemia cells
treated with 0 or 10 μM of zoledronic acid for 7 days (scale bars, 500
μm) (left) and quantification of the number of colony forming cells (n
= 3) (right). d Representative images of paraffin sections of distal
femur bone compartment stained for the osteoclastic marker TRAP at
Day 15 in mice treated with zoledronic acid or vehicle (scale bars, 10
μm). e Micro-CT analysis (left) and quantification (right) of femur
trabecular bone at Day 15 in mice treated with zoledronic acid or
vehicle (n= 8 mice/group). f Serum level of CTX at Day 15 in mice
treated with either zoledronic acid or vehicle (n= 7 mice/group). g
Percentages of mCherry+ leukemia cells at Day 15 in the bone mar-
row, spleen, and blood in mice treated with either zoledronic acid or
vehicle (n= 8 mice/group). h Number of non-leukemia cells at Day 15
in the bone marrow of mice treated with either zoledronic acid or
vehicle (n= 8 mice/group). i Kaplan–Meier survival curves of leu-
kemia mice that were treated with either zoledronic acid or vehicle (n
= 19 mice/group). Throughout, *P < 0.05, ***P < 0.001, ****P <
0.0001. Error bars represented mean ± SD
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symptoms of decreased bone mass in children diagnosed with
ALL [35]. We further investigated the bone loss, and recorded
reduced numbers of osteoblastic cells and enhanced activity
of osteoclasts. RANKL and CSF-1 are critical for osteoclast
differentiation [44]. Mechanistically, we recorded high levels
of Rankl mRNA but not Csf1 mRNA in leukemia cells. We
found 20-fold higher levels of RANKL protein in the bone
marrow supernatant of leukemia mice compared to control
mice, and the leukemia cells induced osteoclast formation in
RAW 264.7 cells, demonstrated to be RANKL-dependent,
documenting an important role of the RANKL signaling
pathway in leukemia-induced bone loss. Our finding that
ALL development severely affects key players in the BMM,
including osteoblastic cells and osteoclasts, is consistent with
their role in regulating the healthy hematopoietic stem cell
niche and in hematopoietic tumors, including myeloid leu-
kemia, myelodysplasia and models of T-ALL [32, 33, 52–57].
The clinical diagnostic findings in children with ALL are
reflected in our model, particularly with respect to hema-
topoiesis, bone and mineral homeostasis. Our observation
of collagen reduction during leukemia development is
consistent with measurements in bone marrow fibroblasts
derived from patients with ALL [58]. The presence of
RANKL mRNA expression has also been reported in the
majority of primary human adult and pediatric B-lineage
ALL specimens [59], providing further clinical corrobora-
tion of our model.
Successful establishment of a leukemia in the bone
marrow involves the co-evolution of the malignant cells,
immune and stromal cells, and the ECM. The findings from
this study show that the non-transformed cell types and the
ECM of the bone marrow are modified early in the devel-
opment of leukemia, most likely via interactions that are
mediated through direct cell contact and secreted cytokines,
chemokines and other factors. Novel insights for hemato-
poietic tumors originated from targeting the microenviron-
ment of myeloid neoplasms. Single-cell transcriptomics has
revealed deregulation of stromal cells in patients with
chronic myeloid leukemia [60]. In murine models of mye-
lodysplastic syndrome and acute myeloid leukemia, nor-
malization of the BMM as well as reinstatement of
osteoblast number and function led to altered disease pro-
gression and prolonged survival [52, 61]. The BMM not
only acts as a sanctuary for leukemia cells but is also a fertile
soil for cancer metastasis [62]. Tumor invasion into bone is
associated with RANKL-mediated osteoclastogenesis [63].
Our preclinical model recapitulates the clinical symp-
toms of bone manifestations in children with pre-B ALL,
and the reported findings unravel the mechanisms of
leukemia-induced bone loss and provide evidence that
zoledronic acid not only compensates for leukemia-
dependent bone fragility but also reduces leukemia bur-
den. Zoledronic acid, a bisphosphonate, is the current
standard of care for treating bone metastases, in conjunc-
tion with standard antineoplastic therapy [64]. Addition-
ally, zoledronic acid has been shown to be safe and
tolerable when administered in combination with che-
motherapy to children with ALL for treatment-related
osteonecrosis [65]. In our study, zoledronic acid was
administered when the disease burden was low in the bone
marrow, highlighting its clinical potential in the setting of
minimal disease, and to alleviate leukemia-induced bone
fragility. Future studies to expand this paradigm into other
genetic subtypes of pre-B ALL, and testing the efficacy of
combining zoledronic acid with contemporary therapy are
warranted. In addition, the role of zoledronic acid in
glucocorticoid-induced bone loss needs to be further
explored. Taken together, these findings provide strong
rationale for targeting the BMM in BCR-ABL1+ pre-B
ALL, with zoledronic acid identified as a potential ther-
apeutic candidate for clinical application.
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